Navigation Links
Study Published in Molecular Therapy Shows that Immune Response to FANG™ Personalized Cancer Therapeutic Correlates with Prolonged Survival in Patients with Advanced Stage Cancer
Date:3/1/2012

DALLAS, March 1, 2012 /PRNewswire/ -- Today Gradalis, Inc., announced that FANG™, the company's tumor-based personalized cancer therapeutic, elicits a robust and lasting immune response, resulting in statistically-significant prolonged survival in patients with advanced stage disease. The Phase 1 study, published today in the Nature Publishing Group journal Molecular Therapy, showed that treatment with FANG significantly increased survival in patients with advanced stage cancer compared to patients who received other forms of treatment in this non-randomized study.

The study evaluated 46 patients with varying tumor types, including melanoma, colorectal, breast, ovarian and hepatocellular cancers. A personalized FANG vaccine was manufactured from tumors removed from 42 of the 46 patients, and 27 patients received one monthly dose of the vaccine for up to 12 months. Twenty-three of the 27 patients receiving FANG achieved stable disease within two months of dose initiation. Median survival for the FANG group was 554 days compared to 132 days for the group that did not receive FANG. (P<0.0001) The "no FANG" group included 18 patients who had vaccine made but did not receive injections due to progression of disease or pursuit of other treatment options. FANG was well tolerated by all patients, and there were no treatment-related serious adverse events.

"The pronounced survival benefit achieved by FANG in patients with multiple tumor types is quite remarkable, and randomized Phase 2 trials are currently underway verifying these results," said John Nemunaitis, M.D., executive medical director of the Mary Crowley Cancer Research Centers and chief medical officer and co-founder of Gradalis. "The benefit is likely attributed to the triad approach which is designed into the vaccine to maximize its effect.  FANG is not only manufactured using each individuals' tumor to assure exposure to the appropriate antigens, but it also activates
'/>"/>

SOURCE Gradalis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BrainCells Inc. Announces the Successful Completion of the Single Ascending Dose Study With BCI-838 and the Initiation of the Multiple Ascending Dose Study
2. Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups
3. Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
4. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
5. Preclinical Study Examines Use of nContacts Technology in Enabling a Percutaneous Device Approach to Epicardial Ablation
6. CHPA Responds to Prescription Mandate Cost Implications Outlined in Oklahoma Economic Impact Study
7. Medical Device Study Examines Use of Emerging Markets and Outsourcing for Clinical Activities
8. Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
9. Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
10. Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono
11. SCOLR Pharmas Partner to Commence Bioequivalence Study of Ondansetron
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences ... the primary efficacy endpoint in the Phase 3 ... placebo for the treatment of painful diabetic neuropathy ... endpoints showed statistically significant improvement over placebo.  In ... was observed.  The results of this trial provide ...
(Date:3/29/2015)... TITUSVILLE, N.J. , March 29, 2015 /PRNewswire/ ... delayed time to relapse compared to placebo in ... 3 clinical study published this week in the ... (JAMA) Psychiatry . Results of ... recent New Drug Application (NDA) filing for three-month ...
(Date:3/27/2015)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... the issuance of an aggregate of 30,000 stock options ... aggregate of 120,500 stock options to employees and consultants ... three years and will be exercisable for a period ... per stock option. About Covalon Covalon ...
Breaking Medicine Technology:BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Covalon Announces Issuance of Stock Options 2
... Sequella, Inc., a clinical-stage biopharmaceutical company focused on ... announced that it received a $694,000 grant supplement as ... of 2009. The ARRA funds, issued through the National ... National Institute of Health (NIH), will assist Sequella to ...
... Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical ... ) focused on bringing the life saving potential ... nationwide and internationally, said today that it has retired ... of $212,959, $250,000 and $285,000. , On October 2, ...
Cached Medicine Technology:Sequella Receives American Recovery and Reinvestment Funding Through the NIH 2Cord Blood America Continues to Reduce Debt; Three Notes Retired 2
(Date:3/30/2015)... V/NO (Virtually No Alcohol) Wines have a ... opening/closing and for reuse. Consumers simply twist the cup, turn ... Yorkers, professionals, and basically anyone can now enjoy a ... back socially or pair with meals at work, home, or ... wine and that means Napa Wine grapes undergo the ...
(Date:3/30/2015)... 30, 2015 South Coast Surety is pleased ... Bond Representative. Richard has been known to the management of ... Richard attended the University of Georgia, majoring in Banking and ... the sales and sales management of business equipment for a ... Most recently, Richard was a senior officer with a National ...
(Date:3/30/2015)... 30, 2015 Considered to be the ... in the global business community, this next generation of ... ante by managing big data and frameworks with virtually ... already powerful analytic and logic features are a technological ... of Lazarus Alliance said “The IT Audit Machine is ...
(Date:3/30/2015)... GREEN, Ohio (PRWEB) March 30, 2015 ... a globally recognized designer and manufacturer of ... and vinyl upholstery options. The new upholsteries ... laboratory, education and custom seating, providing disinfectable, ... are manufactured by renowned textile purveyor CF ...
(Date:3/29/2015)... 2015 Pro Ace Care Heating & ... now provide qualified HVAC technicians that will visit the ... and related systems throughout Vancouver, North Vancouver, Burnaby, Richmond, ... conditioners, heat pumps require regular maintenance from a professional. ... BC Hydro strongly suggest you have it serviced annually ...
Breaking Medicine News(10 mins):Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2Health News:Richard Ford Joins South Coast Surety Contract Surety Team 2Health News:Building on Success: Next Generation of Cyber Crime Prevention Unveiled! 2Health News:BioFit Adds Bleachable Upholstery Options to Seating Line 2Health News:Pro Ace Care Now Provides Qualified HVAC Technicians for Heat Pump Maintenance 2
... , , Mr. Randall Terry and ... city tour, where they held press conferences, performed street theatre, and ... HR 3200. More Details and links at www.OverturnRoe.com , , ... by Randall Terry, founder of Operation Rescue. , , ...
... WASHINGTON, Aug. 26 Loretta King, Acting Assistant Attorney General ... a federal grand jury in Denver has charged Donald Hertz ... the Freedom of Access to Clinic Entrances (FACE) Act for ... The FACE Act makes it a federal crime to injure, ...
... gut noted in study of people with type 1 version ... abnormal immune response to wheat proteins may contribute to type ... people with type 1 diabetes found that nearly half had ... identified genes associated with this abnormal immune response. , "The ...
... genes that may contribute to drug resistance in non-small ... in the open access journal BMC Cancer ... in drug sensitivity and resistance and actual in vitro ... UK, led a team of researchers who assessed the ...
... ... Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop ... ... Drug Information Association (DIA), in cooperation with FDA and PhRMA, will host ...
... , INDIANAPOLIS, Aug. 26 ... gaming interests reported more than $3.6 million in lobbying expenditures ... Indiana public records. , , Individuals employed ... giving more than $228,000 to state political party committees and ...
Cached Medicine News:Health News:Randall Terry, Abortion, and Health Care: Terry comments on disruption of 'Health Care' Town Hall meeting. 'Yes: We disrupted Howard Dean's speech, and we would do it again. Obama and Pelosi must write into the bill: "No Abortion Funding; No mandates for 2Health News:DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop 2Health News:DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop 3Health News:The Gaming Industry Stacks the Deck Against Smokefree Workplaces in Indiana 2
... The Laserex Ultra Q is a ... that provides ophthalmologists with a precise, reliable ... pupillary membranectomy. The system can be ... or opacification of the capsule (posterior capsulotomy), ...
... Laserex Ultra Q is the fundamental capsulotmy laser ... energy delivery and provides 2855% less energy in ... mJs in contemporary systems. This technology eliminates ... the risk of IOL pitting. , , ...
... high-end, mobile ultrasound imaging system. Its Ultrasonix ... amount of processing power for generating images ... imaging systems provide excellent image quality in ... Doppler, Color Doppler Color Angio, Color M-mode, ...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see....
Medicine Products: